Cargando…

Pharmacokinetics and Pharmacodynamics of Fungal Defensin NZX Against Staphylococcus aureus-Induced Mouse Peritonitis Model

Staphylococcus aureus (S. aureus) is one of the most common pathogenic bacteria responsible for causing a life-threatening peritonitis disease. NZX, as a variant of fungal defensin plectasin, displayed potent antibacterial activity against S. aureus. In this study, the antibacterial and resistance c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Xueling, Yang, Na, Mao, Ruoyu, Hao, Ya, Teng, Da, Wang, Jianhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198545/ https://www.ncbi.nlm.nih.gov/pubmed/35722282 http://dx.doi.org/10.3389/fmicb.2022.865774

Ejemplares similares

In Vitro Pharmacodynamics and Bactericidal Mechanism of Fungal Defensin-Derived Peptides NZX and P2 against Streptococcus agalactiae
por: Wu, Yankang, et al.
Publicado: (2022)

Design and Pharmacodynamics of Recombinant Fungus Defensin NZL with Improved Activity against Staphylococcus hyicus In Vitro and In Vivo
por: Liu, He, et al.
Publicado: (2021)

The Pharmacodynamics Study of Insect Defensin DLP4 Against Toxigenic Staphylococcus hyicus ACCC 61734 in Vitro and Vivo
por: Ma, Xuanxuan, et al.
Publicado: (2021)

Antibacterial and immunomodulatory activities of insect defensins-DLP2 and DLP4 against multidrug-resistant Staphylococcus aureus
por: Li, Zhanzhan, et al.
Publicado: (2017)

Molecular Modification of Kex2 P1’ Site Enhances Expression and Druggability of Fungal Defensin
por: Jin, Yanjie, et al.
Publicado: (2023)

Design and pharmacodynamics of recombinant NZ2114 histidine mutants with improved activity against methicillin-resistant Staphylococcus aureus
por: Chen, Huixian, et al.
Publicado: (2017)

Dose Assessment of Cefquinome by Pharmacokinetic/Pharmacodynamic Modeling in Mouse Model of Staphylococcus aureus Mastitis
por: Yu, Yang, et al.
Publicado: (2016)

In Vivo Pharmacokinetics/Pharmacodynamics of Cefquinome in an Experimental Mouse Model of Staphylococcus Aureus Mastitis following Intramammary Infusion
por: Yu, Yang, et al.
Publicado: (2016)

Effective delivery of the anti-mycobacterial peptide NZX in mesoporous silica nanoparticles
por: Tenland, Erik, et al.
Publicado: (2019)

Increased intracellular activity of MP1102 and NZ2114 against Staphylococcus aureus in vitro and in vivo
por: Wang, Xiao, et al.
Publicado: (2018)

Pharmacokinetic/Pharmacodynamic Correlation of Cefquinome Against Experimental Catheter-Associated Biofilm Infection Due to Staphylococcus aureus
por: Zhou, Yu-Feng, et al.
Publicado: (2016)

Synergy between Vancomycin and Nafcillin against Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model
por: Leonard, Steven N.
Publicado: (2012)

Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus
por: Rox, Katharina, et al.
Publicado: (2022)

An Enhanced Variant Designed From DLP4 Cationic Peptide Against Staphylococcus aureus CVCC 546
por: Li, Bing, et al.
Publicado: (2020)

Design and High Expression of Non-glycosylated Lysostaphins in Pichia pastoris and Their Pharmacodynamic Study
por: Shen, Wenluan, et al.
Publicado: (2021)

Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice
por: Li, Bing, et al.
Publicado: (2020)

Site Mutation Improves the Expression and Antimicrobial Properties of Fungal Defense
por: Hao, Ya, et al.
Publicado: (2023)

Killing of Staphylococcus aureus and Salmonella enteritidis and neutralization of lipopolysaccharide by 17-residue bovine lactoferricins: improved activity of Trp/Ala-containing molecules
por: Hao, Ya, et al.
Publicado: (2017)

Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae
por: Wicha, Wolfgang W, et al.
Publicado: (2019)

973. Pharmacokinetic/Pharmacodynamic Evaluation and Dose Optimization of Daptomycin in Pediatric Patients with Staphylococcus aureus Bacteremia
por: Olney, Katie B, et al.
Publicado: (2023)

Internalization, distribution, and activity of peptide H2 against the intracellular multidrug-resistant bovine mastitis-causing bacterium Staphylococcus aureus
por: Wang, Xiao, et al.
Publicado: (2019)

Genetic Variability in Beta-Defensins Is Not Associated with Susceptibility to Staphylococcus aureus Bacteremia
por: Fode, Peder, et al.
Publicado: (2012)

Antibacterial activity of human defensins against Staphylococcus aureus and Escherichia coli
por: Bolatchiev, Albert
Publicado: (2020)

Pharmacodynamics, Population Dynamics, and the Evolution of Persistence in Staphylococcus aureus
por: Johnson, Paul J. T., et al.
Publicado: (2013)

Antimicrobial pharmacodynamics of vancomycin and disulfiram (Antabuse®) in Staphylococcus aureus
por: Chavva, Hasitha, et al.
Publicado: (2023)

395 Impact of vancomycin pharmacokinetic/pharmacodynamic data on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children
por: Yoo, Reenar, et al.
Publicado: (2014)

Determinants of Infection in the Peritoneal Cavity: I. Response to and Fate of Staphylococcus Aureus and Staphylococcus Albus in the Mouse
por: Cohn, Zanvil A.
Publicado: (1962)

The Fungal Defensin Family Enlarged
por: Wu, Jiajia, et al.
Publicado: (2014)

Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice
por: Zhou, Chenguang, et al.
Publicado: (2016)

Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach
por: Garonzik, Samira M., et al.
Publicado: (2016)

Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model
por: Abdul-Mutakabbir, Jacinda C., et al.
Publicado: (2020)

Impact of initial vancomycin pharmacokinetic/pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children
por: Yoo, Reenar, et al.
Publicado: (2021)

Ex Vivo Pharmacokinetics and Pharmacodynamics Modeling and Optimal Regimens Evaluation of Cefquinome Against Bovine Mastitis Caused by Staphylococcus aureus
por: Jiang, Li-jie, et al.
Publicado: (2022)

2532. Pharmacokinetic-Pharmacodynamic Analyses for Ceftobiprole Efficacy Based on Phase 3 Data from Patients with Staphylococcus aureus Bacteremia
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

Human Defensins: A Novel Approach in the Fight against Skin Colonizing Staphylococcus aureus
por: Scudiero, Olga, et al.
Publicado: (2020)

Combined Systems Approaches Reveal a Multistage Mode of Action of a Marine Antimicrobial Peptide against Pathogenic Escherichia coli and Its Protective Effect against Bacterial Peritonitis and Endotoxemia
por: Wang, Xiumin, et al.
Publicado: (2016)

Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Dalbavancin Alone and in Combination with Ceftaroline against Methicillin-Resistant Strains (MRSA) of Staphylococcus aureus
por: Kebriaei, Razieh, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of a Novel Vancomycin Derivative LYSC98 in a Murine Thigh Infection Model Against Staphylococcus aureus
por: He, Peng, et al.
Publicado: (2023)

Determinants of Infection in the Peritoneal Cavity: II. Factors Influencing the Fate of Staphylococcus aureus in the Mouse
por: Cohn, Zanvil A.
Publicado: (1962)

Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update
por: Teng, Renli
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uctah0t9ubgn415vuh9o38pg40